| Literature DB >> 35265685 |
Mattia Vinciguerra1, Marta Sitges2,3,4, Jose Luis Pomar5,6, Silvia Romiti1, Blanca Domenech-Ximenos3,7, Mizar D'Abramo1, Eleonora Wretschko1, Fabio Miraldi1, Ernesto Greco1.
Abstract
Severe tricuspid valve regurgitation has been for a long time a neglected valve disease, which has only recently attracted an increasing interest due to the notable negative impact on the prognosis of patients with cardiovascular disease. It is estimated that around 90% of tricuspid regurgitation is diagnosed as "functional" and mostly secondary to a primary left-sided heart disease and, therefore, has been usually interpreted as a benign condition that did not require a surgical management. Nevertheless, the persistence of severe tricuspid regurgitation after left-sided surgical correction of a valve disease, particularly mitral valve surgery, has been associated to adverse outcomes, worsening of the quality of life, and a significant increase in mortality rate. Similar results have been found when the impact of isolated severe tricuspid regurgitation has been studied. Current knowledge is shifting the "functional" categorization toward a more complex and detailed pathophysiological classification, identifying various phenotypes with completely different etiology, natural history and, potentially, an invasive management. The aim of this review is to offer a comprehensive guide for clinicians and surgeons with a systematic description of "functional" tricuspid regurgitation subtypes, an analysis centered on the effectiveness of existing surgical techniques and a focus on the emergent percutaneous procedures. This latter may be an attractive alternative to a standard surgical approach in patients with high-operative risk or isolated tricuspid regurgitation.Entities:
Keywords: annuloplasty; functional tricuspid regurgitation; prosthetic ring; right ventricle; transcatheter approach
Year: 2022 PMID: 35265685 PMCID: PMC8899114 DOI: 10.3389/fcvm.2022.836441
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Three-dimensional (3D) echocardiography of the tricuspid valve with front view, from the right atrium in diastole and systole where the central coaptation defect (yellow arrow), due to annular dilation, is seen.
Figure 2Cardiac magnetic resonance (CMR) imaging assessing ventricular volumes (A) and four-dimensional (4D) flow image evaluating tricuspid regurgitation (TR) (red arrow) (B).
Summary table with the description of the principal surgical technique in the correction of the functional tricuspid regurgitation (FTR).
|
|
|
|
|
|---|---|---|---|
| Suture bicuspidization | Double pledget-supported mattress suture from the anteroposterior to the posteroseptal commissure | Easily reproducible | frequent technical failures |
| De Vega annuloplasty | Double continuous running suture along anterior and posterior portions of the annulus | Safe, effective, easily reproducible, cheap | Occasional Suture tear: “Bowstring” phenomenon |
| Prosthetic annuloplasty: | Implantation of a prosthetic band or ring | Reduction of recurrent dilatation by a non expandable frame | May Need additional gestures in complex lesions (excessive leaflets tethering) |
| Papillary muscles septalization | The approximation of the anterior PM, attached to the RV free wall and more prone to displacement, toward the interventricular septum | The technique allows to increase the surface of coaptation of leaflets reducing the rate of TR recurrence | Lack of large series reported |
| Leaflet augmentation | Leaflet augmentation using a pericardial patch | The technique allows to increase the leaflets surface improving systolic area closure | Lack of large series reported |
Summary table with the description of the more used transcatheter technique/device of tricuspid valve intervention.
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| Transcatheter tricuspid valve replacement: | Implantation of a prosthetic valve in the tricuspid location or in the vena cava | Alternative option to repair techniques, mainly in patients with degeneration of previous tricuspid valve correction | Lack of experience | |
|
| ||||
| TriClip (Abbott, Chicago, Illinois) | Edge-to-edge repair | Satisfactory reduction of tricuspid regurgitation and improvement in the functional class for patients not suitable for surgery | Lack of comprehensive data on eligible patients | |
| FORMA system (Edwards Lifesciences, Irvine, California) | Implantation of a balloon spacer anchored to right ventricle apex able to reduce regurgitant orifice area | Alternative options to edge-to-edge repair | Invasiveness of the device | |
|
| ||||
| - Trialign (Mitralign Inc, Tewksbury, MA) | System of anchors placed on the anterior and posterior segments of the tricuspid annulus | Reduction of tricuspid annulus diameter in patients not suitable for surgery | Lack of mid-term follow-up data | Safety and Feasibility of the Transcatheter Tricuspid Valve Repair System (Trialign) |
|
| ||||
| - Cardioband system (Edwards Lifesciences, Irvine, CA, USA) | Transcatheter implantation of a prosthetic annulus | Reduction of tricuspid regurgitation in patients deemed inoperable | Lack of mid-term follow-up data | |
Figure 3Transesophageal echocardiography imaging and pre- and postoperative assessment of TR after transcatheter edge-to-edge repair (TEER).